



ELSEVIER

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/jval

Incremental Costs and Cost-Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data

Michael Laxy, PhD^{1,2,3}, Edward C.F. Wilson, PhD⁴, Clare E. Boothby, PhD³, Simon J. Griffin, MD^{3,*}

¹Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Neuherberg, Germany; ²German Center for Diabetes Research (DZD), Neuherberg, Germany; ³Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK; ⁴Cambridge Centre for Health Services Research, University of Cambridge School of Clinical Medicine, Cambridge, UK

ABSTRACT

Background: There is uncertainty about the cost-effectiveness of early intensive treatment versus routine care in individuals with type 2 diabetes detected by screening. **Objectives:** To derive a trial-informed estimate of the incremental costs of intensive treatment as delivered in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care-Europe (ADDITION) trial and to revisit the long-term cost-effectiveness analysis from the perspective of the UK National Health Service. **Methods:** We analyzed the electronic primary care records of a subsample of the ADDITION-Cambridge trial cohort ($n = 173$). Unit costs of used primary care services were taken from the published literature. Incremental annual costs of intensive treatment versus routine care in years 1 to 5 after diagnosis were calculated using multilevel generalized linear models. We revisited the long-term cost-utility analyses for the ADDITION-UK trial cohort and reported results for ADDITION-Cambridge using the UK Prospective Diabetes Study Outcomes Model and the trial-informed cost estimates according to a previously developed evaluation framework. **Results:** Incremental annual costs of intensive treatment over years 1 to 5 averaged

£29.10 (standard error = £33.00) for consultations with general practitioners and nurses and £54.60 (standard error = £28.50) for metabolic and cardioprotective medication. For ADDITION-UK, over the 10-, 20-, and 30-year time horizon, adjusted incremental quality-adjusted life-years (QALYs) were 0.014, 0.043, and 0.048, and adjusted incremental costs were £1,021, £1,217, and £1,311, resulting in incremental cost-effectiveness ratios of £71,232/QALY, £28,444/QALY, and £27,549/QALY, respectively. Respective incremental cost-effectiveness ratios for ADDITION-Cambridge were slightly higher. **Conclusions:** The incremental costs of intensive treatment as delivered in the ADDITION-Cambridge trial were lower than expected. Given UK willingness-to-pay thresholds in patients with screen-detected diabetes, intensive treatment is of borderline cost-effectiveness over a time horizon of 20 years and more.

Keywords: ADDITION trial, cost-effectiveness, intensive treatment, screen-detected diabetes.

© 2017 Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Introduction

Diabetes mellitus is an increasing public health problem, associated with costly micro- and macrovascular complications, reduced quality of life, and premature death [1–4]. The direct and indirect societal costs of diabetes in the United Kingdom are expected to rise from £22 billion in 2010 to £35 billion in 2030, and a large share of this financial burden is attributable to the treatment of diabetic complications in patients with type 2 diabetes [5]. Cost-effective disease management strategies are therefore needed to diminish the burden of the disease on patients and health care systems.

Previous research has shown that intensive multifactorial treatment, including management of cardiovascular risk factors

and glycemic control, reduces the risk of cardiovascular events and is an effective and cost-effective intervention for patients with long-standing diabetes [6–8]. There is also solid evidence that tight control of glucose and blood pressure in newly routinely diagnosed patients is an effective and cost-effective strategy [9–11]. Conversely, little is known about the cost-effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening who, all else being equal, will typically be at an earlier stage in the disease.

The diagnosis of diabetes in routine care settings occurs on average a couple of years after physiological onset [12]. Because of improvements in quality of care and ongoing considerations about population-based screening, this lead time is expected to

Conflicts of interest: None of the authors has competing interests.

* Address correspondence to: Simon J. Griffin, Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.

E-mail: sjg49@medschl.cam.ac.uk

1098-3015/\$36.00 – see front matter © 2017 Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

<http://dx.doi.org/10.1016/j.jval.2017.05.018>

decrease, resulting in a large number of patients who could potentially benefit from early intensive treatment.

The pragmatic cluster-randomized Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care-Europe (ADDITION) trial studied the effect of intensive multifactorial treatment compared with routine care on cardiovascular morbidity and mortality in individuals with type 2 diabetes detected by screening [13,14]. The results showed a nonstatistically significant relative risk reduction in the incidence of the composite cardiovascular end point over a time horizon of 5 years [15].

Of note, levels of cardiovascular risk factors improved modestly over the 5 years of the trial, and a modeling study using the UK Prospective Diabetes Study (UKPDS) risk equations indicated that the cardiovascular risk might be reduced in the long-term [15,16]. Despite this, an initial cost-effectiveness analysis using the UKPDS outcomes model incorporating conservative protocol-driven intervention cost estimates showed that over a time horizon of 30 years, the intervention was not cost-effective according to current UK willingness-to-pay (WTP) thresholds (incremental cost-effectiveness ratio [ICER] ~£37,500 per quality-adjusted life-year [QALY] vs. WTP thresholds of £20,000–£30,000) [17], albeit with substantial decision uncertainty (31% probability that the ICER is <£30,000). Nevertheless, as we know from a previous study that the adherence of general practitioners (GPs) to the trial protocol was not perfect, the incremental costs of the intervention actually delivered might have been lower than expected [18]. Therefore, although our outcomes assessment would be valid, we may have overestimated the incremental cost. Had the intensive treatment regimen been highly cost-effective or cost-ineffective and with a high degree of certainty, further exploration would have been of no value. Nevertheless, given the proximity of the ICER to the (upper) threshold and the level of decision uncertainty, we felt further investigation into the intervention costs was justified.

The objective of this study was therefore to estimate the incremental costs of early intensive treatment as delivered in ADDITION using empirical data from electronic primary care records. We then used this new information to update our previous estimate of the long-term (10–30 years) cost-effectiveness analysis of the ADDITION intervention in the United Kingdom from a National Health Service (NHS) perspective, in a manner consistent with an iterative approach to research and decision making [19–21].

Methods

Study Design and Study Population

The ADDITION-UK (NCT00237549) study was a part of the ADDITION-Europe study and consisted of two phases—a screening program and a pragmatic, cluster-randomized trial comparing the effect of early intensive treatment with that of routine care in individuals with type 2 diabetes detected by screening on a composite end point of cardiovascular morbidity and mortality [13,14]. High-risk individuals without known diabetes aged 40 to 69 years registered in 69 primary care surgeries within a range of 100 miles of the study centers in Cambridge and Leicester were invited for stepwise screening. Of these, 867 individuals (from 49 surgeries) from Cambridge and 159 individuals (from 20 surgeries) from Leicester with type 2 diabetes detected by screening participated in the primary care-based intervention study (ADDITION-UK). Two participants withdrew before year 5, leaving a total study size of 1024 participants. Details of the study protocol including assessment of primary end points and inclusion and exclusion criteria have been published elsewhere [15]. The study

was approved by local ethics committees, and all participants provided informed consent.

Routine Care versus Intensive Treatment

Patients were treated according to the treatment allocation of their surgery. Patients in the routine care arm in Leicester and Cambridge received diabetes care through the UK NHS on the basis of contemporary UK treatment guidelines [22–24]. In the intensive treatment arm, additional features were added to routine care. Some of these intensive treatment features differed between the Leicester and the Cambridge GP surgeries.

In Leicester, intensive treatment was delivered by a specialist team of doctors, nurses, and dieticians within peripatetic community clinics according to the Diabetes Education and Self-Management Programme, which is a group education program delivered by two registered health care professionals in one 6-hour session [25]. The curriculum focuses on lifestyle changes and medication adherence using theories of efficient goal setting and self-efficacy. In addition, in the first year after diagnosis, patients were offered bimonthly appointments with a nurse or a GP in a community peripatetic clinic, and 4-monthly thereafter.

In Cambridge, primary care surgeries received funding for more frequent contacts between patients and practitioners. An initial practice-based academic detailing session conducted by a local diabetologist and an academic GP and interactive practice-based audit and feedback sessions were organized around 6 and 14 months after the initial education session and annually thereafter. Surgery staff received theory-based education materials to hand over to patients, and participants were encouraged to initiate lifestyle changes, to adhere to medication schemes, to self-monitor blood glucose levels if given a glucometer by their practice, and to attend annual health checks.

In addition, in all intensive treatment arm surgeries (Leicester and Cambridge), GPs were advised to follow treatment algorithms for medication with glucose-lowering, angiotensin-converting enzyme inhibiting, lipid-lowering, and platelet-inhibiting medication that were slightly tighter than those in contemporary UK treatment guidelines [13,22–24]. According to the protocol, therapy with glucose-lowering medication was indicated for patients with a glycated hemoglobin A_{1c} (HbA_{1c}) level of more than 6.5%, therapy with angiotensin-converting enzyme inhibitors was indicated for patients with blood pressure higher than 120/80 mm Hg or prevalent cardiovascular disease, statin therapy was indicated for patients with a cholesterol level of higher than 3.5 mmol/L, and aspirin therapy was indicated for all patients without specific contraindications [14].

Incremental Costs of Intensive Treatment in ADDITION-Cambridge

Data source and operationalization

Because of the high cost of assessing and extracting data from electronic primary care records, it was decided in the planning phase of the study that only the records of a subset of the study would be assessed. Records of each participant with a primary end point (i.e., cardiovascular event) plus the records of two random participants from the same GP surgery without a primary end point within the 5-year trial period were accessed. Consequently, the records of 30 participants with a primary end point and of 60 participants without a primary end point from the intensive treatment arm and the records of 33 participants with a primary end point and of 66 participants without a primary end point from the routine care arm were accessed.

These records comprised information on consultations with outpatient health care professionals, prescribed medications, and diagnostic tests from the date of diagnosis (between 2002 and

2005) until the end of the year 2010 (~80,000 observations in total). Costs associated with the use of these services were obtained by multiplying the number of consumed resources by their respective unit prices. Unit prices for consultations with GPs and nurses were extracted from the Personal Social Services Research Unit report on unit costs of health and social care [26]. Prices for all other consultations were taken from the National Schedule of Reference Costs 2009–10 for NHS Trusts [27]. The Prescription Cost Analysis 2010 was used to assign unit prices for prescribed medications [28]. Because of incomplete or ambiguous information from the free-text records, no unit costs could be assigned to around 1% of the recorded used resources. These services were therefore priced according to the mean unit price of used units for the person and year.

On the basis of the study protocol, we allocated cost items to the following categories:

1. costs for consultations related to the trial protocol (contacts with GPs and nurses);
2. costs for medication related to the trial protocol (glucose-lowering drugs, blood pressure-lowering drugs, cholesterol-lowering drugs, and platelet-inhibiting drugs); and
3. costs for all other services (contacts with other primary health care professionals and outpatient specialists, other medications, and diagnostic tests).

Statistical analyses

In the long-term decision model, costs for primary care and medication accrue until a person dies. As input parameters for this decision model, one therefore needs an empirical estimate that describes the difference in average costs between a person alive in the intensive treatment arm and a person alive in the routine care arm. For this, we subdivided the 5-year analysis period into five annual intervals (year 1 to year 5 after diagnosis) and included the observation year in which a person died, but excluded subsequent years from the analysis. After exclusion of 16 participants for whom none or less than 1 year's data were available, 173 participants (from 34 surgeries; mean cluster size = 5; minimum = 2, maximum = 17) provided 841 person-years of data until death. Medication data were missing for 18 of the 173. These costs were imputed with Markov chain Monte-Carlo procedures using model covariates and available annual cost values for consultations, medications, and diagnostic tests. This yielded a final analysis sample of 173 participants with 841 complete observation years.

Here, we first descriptively reported the resource utilization of categories 1 and 2, which has been described in detail elsewhere [18]. Second, we analyzed the annual incremental costs of intensive treatment for each resource utilization category separately using generalized linear models (GLMs). We tested a GLM with identity-link and Gaussian distribution (i.e., ordinary least-squares model), a GLM with log-link and gamma/Poisson distribution, and a GLM with square-root-link and gamma/Poisson distribution (in models with a log link, all zero costs were set to a nominal £1) [29]. Results from these models were very similar; for overall costs, we decided to use the ordinary least-squares model, which is the simplest and yielded the most conservative cost estimates [30]. Models accounted for observation years being clustered into patients and patients being clustered into primary care surgeries (three-level random intercept model) and were adjusted for age, sex, and HbA_{1c} level at diagnosis. We also introduced an interaction term between the year after diagnosis and the treatment status to capture potential trends over time. In a second step, using the same statistical methods, we estimated the total annual incremental costs. To account for the non-random selection of the analyzed subsample, we introduced a

general weighting factor, representing the inverse probability of being included in this analysis, on the basis of the status of having a primary end point [31].

These models yielded mean estimates and standard errors (SEs) for the annual incremental costs of consultations ($\beta_{\text{consultations-Cambridge}}$; $SE_{\text{consultations-Cambridge}}$), medication ($\beta_{\text{medication-Cambridge}}$; $SE_{\text{medication-Cambridge}}$), and the intervention as a whole, including other primary care services ($\beta_{\text{total-Cambridge}}$; $SE_{\text{total-Cambridge}}$). Analyses were performed with SAS 9.3 using the GLIMMIX, MI, and MIANALYZE procedures (SAS Institute, Inc., Cary, NC).

Long-Term Cost-Effectiveness of Intensive Treatment in ADDITION-UK/Cambridge

The long-term cost-effectiveness of ADDITION used the outputs from the UKPDS model as per the original model, with the updated short-term intervention costs from the electronic primary care records. The methods are briefly described here. The analysis is conducted from the perspective of the NHS. Because we have empirical data on the intervention costs only from the Cambridge centers but not from the Leicester centers, we first update the previous cost-effectiveness analyses for ADDITION-UK (Leicester and Cambridge). In a second step we report a separate long-term cost-effectiveness analysis for ADDITION-Cambridge only.

Quality-adjusted life-years

The UKPDS outcomes model v1.3 was applied to simulate the individual accumulated QALYs of patients [17,32]. The UKPDS Outcomes Model is a widely used individual-level state transition simulation model (i.e., a microsimulation model) based on data from a UK population and applicable for the given evaluation context [33]. Its performance has been tested against the ADDITION 5-year outcomes in a previous study showing a moderate calibration and discrimination [34]. The model predicts future events (ischemic heart disease, myocardial infarction, heart failure, stroke, amputation, blindness, and renal failure) and death as a function of several values at diagnosis of diabetes (e.g., sex, ethnicity, and duration of diabetes) and on the basis of values of risk factors at diagnosis and in subsequent years (e.g., smoking, body mass index, cholesterol, high-density lipoprotein, HbA_{1c} level, and systolic blood pressure). Results on risk factor changes and effects on micro- and macrovascular events over the 5-year observation period have been reported previously and are summarized in Appendix 1 in Supplemental Materials found at <http://dx.doi.org/10.1016/j.jval.2017.05.018> [15–17,35]. Utility decrements associated with the modeled events were obtained from the published literature, and the additive method was used for patients with multiple events (see Appendix 2 in Supplemental Materials found at <http://dx.doi.org/10.1016/j.jval.2017.05.018>) [36–38].

Costs

We assumed that the costs for patients in the intensive treatment arm comprise the costs of treatment of complications plus the costs of delivering the intervention itself, including costs for planning and implementation and for extra consultations and medication, whereas in the routine care arm, only the costs of the treatment of complications occur. All costs were calculated in British pounds for the price year 2009/2010. The price year was chosen to maintain comparability with the previous economic analysis [17].

Treatment of events/complications. As for the effects, we used the UKPDS outcomes model v1.3 to estimate the per-patient costs for the treatment of events and complications [32]. Unit costs for

Table 1 – Protocol-based and empirical cost estimates (£) used in the initial [17] and updated base-case cost-effectiveness analyses.

Cost component	Center	Per protocol [*]				Trial-based [†]			
		Accumulated		Annually		Accumulated		Annually	
		Mean	SE	Mean	SE	Mean	SE	Mean	SE
<i>Upfront costs</i>									
Planning and implementation	Cambridge (n = 452)	375.1	–	–	–	375.1	0.0	–	–
	Leicester (n = 61)	71.2	–	–	–	71.2	0.0	–	–
<i>Years 1–5[‡]</i>									
Extra consultations	Cambridge (n = 452)	311.3 [§]	–	62.3	–	145.5	161.5	29.1 [¶]	32.3 [¶]
	Leicester (n = 61)	880.1 [§]	–	176.0	–	880.1	976.9 [#]	176.0	195.4 [#]
Extra medication	Cambridge (n = 452)	262.5	–	52.5	–	273.0	142.5	54.6 [¶]	28.5 [¶]
	Leicester (n = 61)	262.5	–	52.5	–	262.5	137.0 [#]	52.5	27.4 [#]
<i>Year 6 until ...</i>									
<i>end of observation period</i>									
<i>death or end of observation period</i>									
Extra medication (years 6–10)	Cambridge (n = 452)	199.6 ^{**}	–	52.5	–	183.7 ^{††}	95.9	54.6 [¶]	28.5 [¶]
	Leicester (n = 61)	199.6 ^{**}	–	52.5	–	203.4 ^{††}	106.2 [#]	52.5	27.4 [#]
Extra medication (years 6–20)	Cambridge (n = 452)	509.1 ^{**}	–	52.5	–	386.9 ^{††}	201.9	54.6 [¶]	28.5 [¶]
	Leicester (n = 61)	509.1 ^{**}	–	52.5	–	434.9 ^{††}	227.0 [#]	52.5	27.4 [#]
Extra medication (years 6–30)	Cambridge (n = 452)	728.5 ^{**}	–	52.5	–	444.3 ^{††}	231.9	54.6 [¶]	28.5 [¶]
	Leicester (n = 61)	728.5 ^{**}	–	52.5	–	520.3 ^{††}	271.6 [#]	52.5	27.4 [#]

SE, standard error.
^{*} Protocol-based cost estimates according to the internal accounting of Tao et al. [17].
[†] Empirical cost estimates according to the analysis on a subsample of the ADDITION sample.
[‡] Accumulated costs described without discounting.
[§] Costs were assumed to occur from years 1 to 3.
^{||} Annual costs if distributed over 5 y.
[¶] βs and SEs extracted from Table 3.
[#] SEs in Leicester were assumed to be proportional to the ones in patients from Cambridge.
^{**} Calculated using $\sum_{t=6}^{\text{time horizon}} \frac{\beta_{\text{annual medication cost}}(t)}{(1 + 0.035)^t}$.
^{††} Calculated using $\sum_{t=6}^{\text{LE}} \frac{\beta_{\text{annual medication cost}}(t)}{(1 + 0.035)^t}$, where modeled life expectancy (LE) for the 10-, 20-, and 30-y time horizons averaged ~9.4, ~15.2, and ~17.0 y in Cambridge and ~9.6, ~16.3, and ~19.3 y in Leicester.

the treatment of complications were obtained from the UKPDS study and other published literature (see Appendix 2 in Supplemental Materials) [37–39]. Again, the additive method was used to calculate costs in case of multiple complications or events.

Planning and implementation. The previously published internal accounting showed average per-patient costs of £375 in Cambridge and £71 in Leicester for the planning and implementation (teaching and feedback sessions) of the study [17]. These values were also used in this analysis.

Extra consultations and medication. For Cambridge (n = 867), we used the empirically derived cost estimates ($\beta_{\text{consultations-Cambridge}}$, $SE_{\text{consultations-Cambridge}}$, $\beta_{\text{medication-Cambridge}}$, and $SE_{\text{medication-Cambridge}}$). For Leicester (n = 159), no empirical cost data were available, and we used the cost estimates from the internal accounting [17], which were used for the protocol-based cost-effectiveness analysis [17]: $\beta_{\text{consultations-Leicester}}$ (annual per-patient costs for extra consultations in years 1–5) = £880/5 = £176 and $\beta_{\text{medication-Leicester}}$ (annual per-patient costs for extra medication in years 1–5 and thereafter) = £52.5. A detailed description of the protocol-based cost estimates is presented in Table 1.

Statistical analysis

For patients in both trial arms, the individual 10-, 20-, and 30-year accumulated QALYs and costs for the treatment of complications were projected by running simulations with 1000 inner model

loops and 100 bootstraps of the UKPDS outcomes model v.1.3 with a cycle length of 1 year [32]. Both costs and QALYs were discounted at a rate of 3.5% according to the guidelines of the National Institute for Health and Care Excellence (NICE) [40]. Some minor adjustments to the input data were performed before running the model: Patients with unknown or unclassifiable ethnicity were excluded from the analysis (n = 25), and values of atrial fibrillation, peripheral vascular disease, ischemic heart disease, congestive heart failure, amputation, blindness, and renal failure, which were not collected in ADDITION, were set to 0. Furthermore, missing values of input variables were imputed via Markov chain Monte-Carlo procedures (n = 5 imputations), and means and SEs were subsequently derived using Rubin's rules (information on the missing data is provided in Appendix 3 in Supplemental Materials found at <http://dx.doi.org/10.1016/j.jval.2017.05.018>).

As a base-case scenario, we calculated the incremental cost-effectiveness for ADDITION-UK, including patients from Cambridge and Leicester. To the simulated costs for the treatment of complications that occur in both treatment arms, for patients in the intervention arm, we added the per-patient mean costs for planning and implementation of the intervention, the discounted per-patient mean costs for extra consultations in years 1 to 5 ($\sum_{t=1}^5 \frac{\beta_{\text{consultations}}(t)}{(1 + 0.035)^t}$), and the discounted per-patient mean costs for medication until death ($\sum_{t=1}^{\text{LE}} \frac{\beta_{\text{medication}}(t)}{(1 + 0.035)^t}$). Life expectancy (LE) for the 10-, 20-, and 30-year time horizons averaged approximately 9, 15, and 17 years, respectively. SEs of the different cost components were summed in an additive manner. In parallel to

Table 2 – Baseline characteristics of the ADDITION population trial cohort.

Characteristic	ADDITION-UK (Cambridge + Leicester)*		ADDITION-Cambridge analysis subsample (weighted†)	
	IT (n = 513)	RC (n = 511)	IT (n = 82)	RC (n = 91)
Primary endpoint during follow-up period (%)	7.2	7.5	6.8	7.7
Sex, female (%)	36.6	40.7	40.8	39.4
Age (y), mean ± SD	61.1 ± 7.2	60.1 ± 7.5	61.8 ± 7.3	61 ± 7.1
BMI, mean ± SD (kg/m ²)	33.1 ± 5.6	33.0 ± 5.9	33.4 ± 5.2	34 ± 5.7
Total cholesterol (mmol/L), mean ± SD	5.3 ± 1.1	5.5 ± 1.2	5.4 ± 1.1	5.6 ± 1.2
HDL (mmol/L), mean ± SD	1.17 ± 0.4	1.2 ± 0.3	1.2 ± 0.3	1.2 ± 0.3
Systolic blood pressure (mm Hg), mean ± SD	142.0 ± 20.1	143.1 ± 19.4	141.6 ± 21	142.5 ± 20.6
HbA _{1c} (%), mean ± SD	7.3 ± 1.7	7.3 ± 1.7	7.7 ± 2.2	7.4 ± 1.7

BMI, body mass index; HbA_{1c}, glycated hemoglobin; HDL, high-density lipoprotein; IT, intensive treatment; RC, routine care.

* Of the total sample (1026), 2 withdrew from the study.

† Weighting factor: inverse probability of being included in the study on the basis of the status of having a primary end point.

the method described by Tao et al. [17], the resulting means and SEs of QALYs and costs at patient level were used to conduct a bootstrap analysis (n = 500) adjusting for center, age at diagnosis, sex, and HbA_{1c} level at baseline.

We report the ICERs for the 10-, 20-, and 30-year time horizons and the probability of the intervention being cost-effective given a WTP threshold of £30,000. We also illustrate the decision uncertainty with a scatterplot in the cost-effectiveness plane and a cost-effectiveness acceptability curve.

Analyses of modeled scenarios were conducted using the UKPDS outcomes v1.3 model and Microsoft Excel (Redmond, WA). The article was written according to the Consolidated Health Economic Evaluation Reporting Standards statement [41].

Sensitivity analysis

In additional analyses, we assumed that not only were the costs of medication incurred until death, but the total incremental primary care costs, including costs of consultations and other primary care services, were also incurred until death

$$\left(\sum_{t=1}^{LE} \frac{\beta_{\text{total}}(t)}{(1 + 0.035)^t} \right).$$

One-way sensitivity analyses were performed on the main model for ADDITION-UK with varying treatment costs, utility decrements, and discount rates using the 30-year simulation data. The range for the discount rate (0%–5%) was guided by NICE guidelines suggesting a discount rate of 3.5% as base case and 1.5% in sensitivity analyses [42]. The range for utility decrements and unit costs (–20% to +20%) was guided by the coefficient of variation of parameter estimates that averaged approximately 8% to 12% in the data sources from which the input parameters were taken [36,39].

We also adjusted our models to most recently available prices because relative prices, particularly for medications, might have changed substantially since 2010. The Personal Social Services Research Unit Costs of Health and Social Care 2010 and 2015 [43,44], the British National Formulary for 2010 and 2016 [45], and the NHS trust reference cost schedules for 2009/2010 and 2015/2016 [46,47] were used to retrieve relative price changes for GP and nurse contacts, for cardiometabolic medications, and for hospitalizations of diabetes-related complications (see Appendix 4 in Supplemental Materials found at <http://dx.doi.org/10.1016/j.jval.2017.05.018>).

Results

Study Design and Study Population

Baseline characteristics of the total UK sample and of the weighted Cambridge subsample are presented in Table 2. The

mean age of the UK sample was around 61.5 years. No substantial differences were observed between the UK sample (n = 1024) and the weighted Cambridge subsample from which empirical cost data were available (n = 173).

Incremental Costs in ADDITION-Cambridge

The primary care cost components for patients in the intensive treatment and routine care arm are illustrated in Figure 1. Respective resource utilization for contact with health care professionals and medication related to the trial protocol is illustrated in Appendix 5 in Supplemental Materials found at <http://dx.doi.org/10.1016/j.jval.2017.05.018>. Most costs are attributable to contacts with GPs, metabolic and cardioprotective medication, and other types of medications. The annual costs for contacts with GPs, nurses, and other health care professionals and the annual costs for glucose-lowering drugs, blood pressure-lowering drugs, lipid-lowering drugs, aspirin, other medication, and diagnostic tests stayed constant or increased over the 5-year time horizon. Significant cost differences between the intensive treatment arm and the routine care arm were observed only for glucose-lowering and lipid-lowering drugs.

The mean incremental annual costs of intensive treatment are presented in Table 3. Total incremental annual costs per patient over the 5-year time period averaged £92 ($\beta_{\text{total-Cambridge}} = 92.0$; $SE_{\text{total-Cambridge}} = 115.4$) using a GLM with a Gaussian distribution and an identity link. Incremental annual costs per patient for GP/nurse consultations and for metabolic/cardioprotective medication averaged £29 ($\beta_{\text{consultation-Cambridge}} = 29.1$; $SE_{\text{consultation-Cambridge}} = 33.0$) and £55 ($\beta_{\text{medication-Cambridge}} = 54.6$; $SE_{\text{medication-Cambridge}} = 28.5$), respectively. The incremental costs for other services were £6 ($\beta = 5.7$; $SE = 89.1$). About 4% of the variation in the total incremental costs was explained by the clustering of patients into surgeries (intraclass correlation coefficient = 0.036). A detailed analysis of the cost pattern over time showed that the cost difference varied considerably between the observation years (see Appendix 6 in Supplemental Materials found at <http://dx.doi.org/10.1016/j.jval.2017.05.018>). Omitting the weighting factor or performing a complete case analysis (without imputed observation years) altered the results only marginally.

Long-Term Cost-Effectiveness in ADDITION-UK

Table 4 presents the crude accumulated QALYs and costs over the 10-, 20-, and 30-year time horizon for ADDITION-UK and ADDITION-Cambridge. Table 5 presents the adjusted incremental QALYs, costs, and ICERs for ADDITION-UK and




Fig. 1 – Adjusted means of annual primary care costs according to IT (gray) and RC (black) in years 1–5 (generalized linear model with a gamma distribution and log link with a main effect for the intervention and for time since diagnosis and an interaction term between intervention and time; adjusted for sex and age of diagnosis and baseline HbA_{1c}; accounted for patients being clustered in GP surgeries and observations clustered in patients) no SE is available for the cost difference. CI, confidence interval; GP, general practitioner; HbA_{1c}, glycated hemoglobin A_{1c}; HCP, health care professional; IT, intensive treatment; RC, routine care; SE, standard error.

ADDITION-Cambridge. Because of larger cardiovascular risk factor reductions in Leicester [16,35], incremental QALYs in ADDITION-UK were higher than in ADDITION-Cambridge.

Nevertheless, because of higher implementation costs in Leicester incremental costs in ADDITION-UK were higher than in ADDITION-Cambridge. Resulting ICER point estimates for the

Table 3 – Adjusted means of annual primary care costs according to IT and RC in the years 1–5[†].

	Total		Consultations (ADDITION)		Medication (ADDITION)		Other primary care services	
	Mean	SE	Mean	SE	Mean	SE	Mean	SE
IT	906.3	82.2	266.4	23.2	182.1	19.9	454.1	63.8
RC	814.3	81	237.2	23.5	127.6	20.4	448.3	62.3
Difference	92	115.4	29.1	33	54.6	28.5	5.7	89.1
	(β_{total}^{\dagger})	(SE_{total}^{\dagger})	($\beta_{consultation}^{\dagger}$)	($SE_{consultation}^{\dagger}$)	($\beta_{medication}^{\dagger}$)	($SE_{medication}^{\dagger}$)		

GP, general practitioner; HbA_{1c}, glycated hemoglobin; IT, intensive treatment; RC, routine care; SE, standard error.

* Generalized linear regression model with a Gaussian distribution and identity link with a main effect for the intervention and for time since diagnosis and an interaction term between intervention and time; adjusted for sex and age of diagnosis and baseline HbA_{1c}; accounted for patients being clustered in GP surgeries and observations clustered in patients; model based on 841 observation years from 173 patients.

[†] Estimate used for long-term cost-effectiveness model.

Table 4 – Crude cumulative cost and QALYs according to IT and RC.

Time horizon	RC					IT				
	n	Crude costs		Crude QALYs		n	Crude costs		Crude QALYs	
		Mean	SE	Mean	SE		Mean	SE	Mean	SE
<i>ADDITION-UK (Leicester and Cambridge)</i>										
10 y	501	6,157	332	6.45	0.08	498	7,256	879	6.40	0.09
20 y	501	11,175	867	9.32	0.21	498	12,392	1,614	9.16	0.23
30 y	501	13,181	1,325	10.08	0.30	498	14,308	2,110	9.82	0.31
<i>ADDITION-Cambridge</i>										
10 y	501	6,228	341	6.42	0.08	498	7,199	77,265	6.39	0.09
20 y	501	11,208	885	9.21	0.22	498	12,291	149,687	9.11	0.23
30 y	501	13,102	1,324	9.89	0.31	498	14,170	197,961	9.76	0.31

IT, intensive treatment; QALY, quality-adjusted life-year; RC, routine care; SE, standard error.

10-, 20-, and 30-year time horizon were £71,232/QALY, £28,444/QALY, and £27,549/QALY for ADDITION-UK and £96,570/QALY, £36,115/QALY, and £29,588/QALY, for ADDITION-Cambridge.

Figure 2 shows the scatterplot of the 10-, 20-, and 30-year QALY and cost pairs of bootstrap replications in the cost-effectiveness plane and the cost-effectiveness acceptability curve. For all three time horizons, most of the points lie in the northeast quadrant. For ADDITION-UK 0.7%, 53.5%, and 56.0% and for ADDITION-Cambridge 0.9%, 39.5% and 50.0% are positioned below the £30,000/QALY WTP threshold.

Sensitivity Analyses

Incorporating total incremental primary care costs, including costs of consultations and other primary care services, yielded a 30-year ICER point estimate of £33,000/QALY for ADDITION-UK and of £38,000/QALY for ADDITION-Cambridge. The one-way sensitivity analysis with varying unit costs, discount rates, and utility decrement for ADDITION-UK is illustrated in the tornado diagram of Figure 3. It shows that for the specified ranges the ICER point estimate for ADDITION-UK lies close to or below the threshold of £30,000/QALY. Results from the sensitivity analysis for ADDITION-Cambridge are similar (not shown). Between 2010 and 2015/2016, relative prices increased by 44% for GP and nurse contacts and by 15% for unit costs for the treatment of diabetes complications, and they decreased by 41% for relevant cardiometabolic medications (see Appendix 4 in Supplemental

Materials). The price change-adjusted models resulted in ICERs of £25,000/QALY for ADDITION-UK and £27,000/QALY for ADDITION-Cambridge.

Discussion

There is uncertainty about the costs and the cost-effectiveness of early intensive multifactorial treatment as delivered in the ADDITION trial. On the basis of electronic primary care records of a subsample of the trial cohort, we analyzed the incremental costs of delivered intensive treatment in ADDITION-Cambridge. Following an iterative framework of decision making in health care, we used these empirical cost estimates to update the previously published cost-effectiveness analysis for ADDITION-UK and present estimates for ADDITION-Cambridge. The results show that the intervention was delivered at lower costs than previously assumed and that there is a moderate likelihood that the intervention will be cost-effective over a time horizon of 30 years.

The difficulty of decision making in the context of chronic diseases is that potential positive effects of treatment, that is, reduction in cardiovascular events and premature death, are likely to occur far from the time when interventions are delivered to patients. This issue is of particularly high relevance for interventions that target populations at a very early stage in disease progression, as in the case of treatment for individuals

Table 5 – Adjusted incremental costs and QALYs and ICER*.

Time horizon	Adjusted incremental cost (95% CI)	Adjusted incremental QALYs (95% CI)	ICER (£)	P†
<i>ADDITION-UK (Leicester and Cambridge)</i>				
10 y	1,021 (920 to 1,120)	0.0143 (−0.0015 to 0.0294)	71,232	0.007
20 y	1,217 (1,029 to 1,406)	0.0428 (0.0034 to 0.0817)	28,444	0.535
30 y	1,311 (1,072 to 1,559)	0.0476 (0.0011 to 0.0932)	27,549	0.560
<i>ADDITION-Cambridge</i>				
10 y	927 (831 to 1,017)	0.0096 (−0.0079 to 0.0267)	96,570	0.009
20 y	1,086 (909 to 1,268)	0.0301 (−0.0144 to 0.0708)	36,115	0.395
30 y	1,157 (908 to 1,414)	0.0391 (−0.0107 to 0.0892)	29,588	0.500

CI, confidence interval; HbA_{1c}, glycated hemoglobin; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; SE, standard error.

* Means and SEs of QALYs and costs at patient level were used to conduct a bootstrap analysis (n = 500) adjusting for center, age at diagnosis, sex, and HbA_{1c} level at baseline.

† Probability that the ICER is <£30,000/QALY.




Fig. 2 – Cost-effectiveness planes showing pairs of 10-, 20-, and 30-year incremental costs and QALYs from bootstrap samples, and cost-effectiveness acceptability curves showing the probability of IT being more cost-effective than RC on the basis of net benefit values from bootstrap samples over a time horizon of 10, 20, and 30 y. IT, intensive treatment; QALY, quality-adjusted life-year; RC, routine care.

with type 2 diabetes detected by screening. Because decisions in health care often need to be made promptly and cannot be postponed until evidence from long-term trials is available,

models that simulate the natural course of the disease, and with it the expected effects (QALYs) and costs, have been established as helpful tools [48]. Simulation models, however, rely on a set of




Fig. 3 – Tornado diagram showing the influence of changing different parameters that contribute to the ICER in long-term cost-effectiveness modeling analysis. Choice of discount rate has the greatest impact on the ICER (higher discount rate, unit costs, and lower utility decrements all associated with higher point estimate ICER). ICER, incremental cost-effectiveness ratio.

assumptions and input parameters that crucially determine the results of the simulation.

To assess the cost-effectiveness of the ADDITION intervention, we previously used the UKPDS outcomes model, which projects accumulated QALYs and costs over a 10-, 20-, and 30-year time horizon. This analysis showed that ICERs were only moderately sensitive to the used input parameters (unit costs for treatment of events, utility decrements for events, and discount rate), but highly sensitive to the assumptions on the costs of the intervention itself [17]. The input parameter for the incremental treatment costs was solely estimated on the trial protocol assuming 100% protocol adherence. To receive an empirical, trial-informed estimate, we therefore analyzed the electronic primary care records of a subset of the ADDITION-Cambridge trial cohort and used these data to update the long-term cost-effectiveness model.

The results of the empirical analysis show that the incremental per-patient costs for actually delivered consultations were lower than expected (£145 empirical vs. £311 protocol-based for years 1–5), but that the assumption for extra medication was appropriate (£54.6 empirical vs. £52.5 protocol-based annually; see Table 1). The former suggests that GPs did see their patients more often, but not to the extent for which they were reimbursed within the trial. The latter indicates that incremental costs for medication actually delivered were as high as the per-protocol estimated costs, which were based on the assumption of 100% protocol adherence with generic drug agents. This is surprising because we know that the protocol adherence was not perfect [18]. A possible explanation for this finding is that the reduction in costs resulting from the suboptimal medication adherence has been canceled out by an increase in costs resulting from the high usage of nongeneric drugs observed in both treatment arms. In more detailed analyses, for example, we observed that after the year 2003 when simvastatin went off patent, more than 35% of statin prescriptions were still for the much more expensive atorvastatin. Of note, costs for primary care services that were not directly related to the trial protocol were almost equal in both trial arms.

Revisiting the previously developed robust evaluation framework [17] with the empirical trial-informed cost estimates shows that the intervention has a moderate likelihood of being cost-effective over a time horizon of 30 years, assuming the higher UK NICE WTP threshold of £30,000/QALY. Our sensitivity analyses also indicated that the intervention might be cost-effective with most recent prices.

This study also shows that empirical information on the incremental costs of the delivered intervention is invaluable for the economic evaluation of this trial. Unknown protocol adherence and the magnitude of generic drug usage can lead to a considerable over- or underestimation of incremental costs. Trialists should consider whether there could be value in measuring adherence to protocol when designing future pragmatic studies.

Comparison with the Initial Cost-Effectiveness Analysis

The cost-effectiveness analysis in this study is based on a previously developed modeling framework [17]. A few minor methodological adaptations, however, have been made. Supported by the empirical data, annual costs for extra consultations in ADDITION-Cambridge were assumed to occur until year 5 and not only until year 3. Furthermore, the uncertainty of incremental costs was considered in the cost-effectiveness model by incorporating the SEs of the empirically derived incremental cost estimates in an additive manner. In the initial long-term cost-effectiveness analysis we also erroneously presumed that the mean costs for additional medication would be incurred until the end of the 10-, 20-, and 30-year simulation time horizon

independently of individual simulated deaths of participants [17]. In this study, we took the more plausible assumption that costs for extra medication will occur until a person dies or reaches the end of the simulated time horizon. Applying this assumption to the previous cost-effectiveness analyses would have led to ICER point estimates of around £83,000/QALY, £32,000/QALY, and £30,000/QALY for a 10-, 20-, and 30-year simulation time horizon, respectively. The decrease in the ICER in our study can be explained by the lower frequency of extra consultations compared with the per-protocol assumed costs in the ADDITION-Cambridge sample (see Table 1).

Strengths and Limitations

The main strength of this study is the use of empirical data from electronic primary care records from a subsample of the ADDITION-Cambridge trial sample. The use of these data provided a unique insight into the cost structure of intensive treatment as delivered in the ADDITION trial and allowed us to perform a detailed analysis of incremental cost components. This allowed us to revisit the cost-effectiveness analyses with the updated cost estimates using a previously developed robust evaluation framework and incorporated the uncertainty around the empirically derived cost estimates.

There are also some limitations that need to be taken into account. First and most importantly, the risk equations of the UKPDS outcomes model v1.3 were derived from a historical cohort followed from 1977 to 1997. Because the general quality of diabetes care has improved since then, the model overestimates the absolute cardiovascular disease risk in current populations. This finding was replicated in a previous validation study based on ADDITION data. Nevertheless, this validation study also showed that the model performed reasonably well in the prediction of incremental cardiovascular event rates in the ADDITION-UK sample [34]. Second, the input parameters for costs and utility decrements associated with the modeled events might be outdated and updating for inflation will not account for changes in relative prices. We therefore performed sensitivity analyses on these parameters, which showed that the results were only moderately sensitive toward variation in these parameters. Third, we had empirical information on primary care costs for only about 20% of the ADDITION-Cambridge trial cohort. We therefore kept the protocol-based assumptions for participants from Leicester in the analysis for ADDITION-UK, but performed separate analyses restricted to ADDITION-Cambridge participants. We further assigned mean cost estimates instead of individual-level costs to patients from Cambridge and Leicester. Fourth, because of the relatively small sample size, the clustering of patients into GP practices, and the nonavailability of information on resource utilization before randomization, the uncertainty around the cost estimates remained relatively large. Fifth, we had only empirical information on primary care contacts. We therefore used the risk factor profile of participants together with the UKPDS outcomes model to predict complications and costs (including hospital costs) associated with those complications. Nevertheless, we do not know whether the intervention provoked or prevented other unexpected care use that is not captured by the model and also not by our empirical primary care cost analyses. This shortcoming could have biased the cost estimates and ICERs in either direction. Sixth, we estimated incremental costs for medication on the basis of prescriptions issued. We, however, do not know how many of these were actually dispensed and we therefore probably overestimated the absolute (and incremental) costs for medications. Other limitations, such as the fact that the UKPDS outcomes model does not incorporate all diabetes-related complications and that the ADDITION-UK sample does not adequately represent UK ethnic diversity,

limiting its external validity, have been discussed in detail by Tao et al. [17].

Conclusions

Revisiting and correcting the initial cost-effectiveness analyses with empirical trial-informed cost estimates suggests that money spent on intensive treatment in individuals with type 2 diabetes detected by screening might be borderline cost-effective according to conventional UK WTP thresholds. Nevertheless, the results need to be interpreted with caution because the projection of trial data over a long time horizon is almost always associated with substantial uncertainty.

Acknowledgments

We gratefully acknowledge the contribution of all participants, practice nurses, and general practitioners in the ADDITION-Cambridge study (a full list of participating practices is given later) and Kit Coutts and Dr Rebecca Simmons for their contribution to data collection. We also acknowledge the contribution of the trial steering committee (Professors Nigel Stott, John Weinman, Richard Himsworth, and Paul Little) and Professor Jane Armitage and Dr Louise Bowman who adjudicated the end points. ADDITION-Cambridge was supported by the Wellcome Trust (grant reference no. G061895), the Medical Research Council (grant reference no. G0001164), NHS R&D support funding (including the Primary Care Research and Diabetes Research Networks), and the National Institute for Health Research. We received an unrestricted grant from the University of Aarhus, Denmark, to support the ADDITION-Cambridge trial. Bio-Rad provided equipment to undertake capillary glucose screening by HbA_{1c} in general practice. S. J. Griffin is a National Institute for Health Research (NIHR) senior investigator E Wilson is part-funded by the NIHR Cambridge Biomedical Research Centre. The Primary Care Unit is supported by NIHR Research funds. S. J. Griffin received support from the Department of Health NIHR Programme Grant funding scheme (grant no. RP-PG-0606-1259). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The Primary Care Unit and the Medical Research Council Epidemiology Unit at the University of Cambridge jointly coordinated the study.

Besides the authors, the ADDITION-Cambridge study team included Rebecca Abbott, Amanda Adler, Judith Argles, Gisela Baker, Rebecca Bale, Ros Barling, Daniel Barnes, Mark Betts, Sue Boase, Sandra Bovan, Gwen Brierley, Ryan Butler, James Brimbicombe, Parinya Chamnan, Sean Dinneen, Pesheya Doubleday, Justin Basile Echouffo-Tcheugui, Sue Emms, Mark Evans, Tom Fanshawe, Francis Finucane, Philippa Gash, Julie Grant, Wendy Hardeman, Robert Henderson, Susie Hennings, Muriel Hood, Garry King, Ann-Louise Kinmonth, Georgina Lewis, Christine May Hall, Joanna Mitchell, Richard Parker, Nicola Popplewell, A. Toby Prevost, Emanuella De Lucia Rolfe, Richard Salisbury, Lincoln Sargeant, Rebecca Simmons, Stephen Sharp, Megan Smith, Stephen Sutton, Nicholas Wareham, Liz White, Fiona Whittle, and Kate Williams. We also thank the Cambridge University Hospitals NHS Foundation Trust Department of Clinical Biochemistry and the NIHR Cambridge Biomedical Research Centre Core Biochemistry Assay Laboratory for carrying out the biochemical assays and the following groups within the Medical Research Council Epidemiology Unit: data management (Adam Dickinson), information technology (Iain Morrison and Rich Hutchinson), technical (Matt Sims), and field epidemiology (Paul Roberts, Kim Mwanza, James Sylvester, Gwen Brierley, and Jaimie

Taylor). ADDITION-Cambridge practices: Acorn Community Health Centre, Arbury Road Surgery, Ashwell Surgery, Birchwood Surgery, Bridge Street Medical Centre, Brookfields & Cherry Hinton, Broomfields, Buckden Surgery, Burwell Surgery, Cambridge Surgery, Cedar House Surgery, Charles Hicks Centre, Chequers Lane Surgery, Clarkson Surgery, Cornerstone Practice, Cornford House Surgery, Cottenham Surgery, Cromwell Place Surgery, Dr Smith and Partner (Cambridge), East Field Surgery, Ely Surgery, Freshwell Health Centre, George Clare Surgery, Great Staughton Surgery, Harston Surgery, Health Centre (Eaton Socon), Hilton House, John Tasker House, Lensfield Medical Practice, Manea Surgery, Mercheford House, Milton Surgery, Nene Valley Medical Practice, Nevells Road Surgery, New Roysia Surgery, Northcote House Surgery, Nuffield Road Medical Centre, Orchard Surgery, Orchard House Surgery, Orton Medical Practice, Park Medical Centre, Paston Health Centre, Peterborough Surgery, Petersfield Medical Practice, Prior's Field Surgery, Queen Edith's Medical Practice, Queen Street Surgery, Rainbow Surgery, Ramsey Health Centre, Riverside Practice, Roman Gate Surgery, Rosalind Franklin House, South Street Surgery, Thaxted Surgery, The Health Centre (Bury St Edmunds), The Old Exchange, The Surgery Stanground, Townley Close Health Centre, Trumpington Street Medical Practice, Werrington Health Centre, and York Street Medical Practice.

Supplemental Materials

Supplemental material accompanying this article can be found in the online version as a hyperlink at <http://dx.doi.org/10.1016/j.jval.2017.05.018> or, if a hard copy of article, at www.valueinhealthjournal.com/issues (select volume, issue, and article).

REFERENCES

- [1] Narayan KM, Gregg EW, Fagot-Campagna A, et al. Diabetes—a common, growing, serious, costly, and potentially preventable public health problem. *Diabetes Res Clin Pract* 2000;50:S77–84.
- [2] Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clin Diabetes* 2008;26:77–82.
- [3] Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: a population study using record linkage. *Diabetes Care* 2000;23:1103–7.
- [4] Schunk M, Reitmeir P, Schipf S, et al. Health-related quality of life in subjects with and without type 2 diabetes: pooled analysis of five population-based surveys in Germany. *Diabet Med* 2012;29:646–53.
- [5] Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. *Diabet Med* 2012;29:855–62.
- [6] Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003;348:383–93.
- [7] Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. *Diabetes Care* 2008;31:1510–5.
- [8] Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008;358:580–91.
- [9] Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–89.
- [10] Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. *N Engl J Med* 2008;359:1565–76.
- [11] Clarke PM, Gray AM, Briggs A, et al. UKPDS 72 United Kingdom Prospective Diabetes Study. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). *Diabetologia* 2005;48:868–77.
- [12] Porta M, Curletto G, Cipullo D, et al. Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. *Diabetes Care* 2014;37:1668–74.

- [13] Echouffo-Tcheugui JB, Simmons RK, Williams KM, et al. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. *BMC Public Health* 2009;9:1471–2458.
- [14] Lauritzen T, Griffin S, Borch-Johnsen K, et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. *Int J Obes Relat Metab Disord* 2000;24:S6–11.
- [15] Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. *Lancet* 2011;378:156–67.
- [16] Black JA, Sharp SJ, Wareham NJ, et al. Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial. *Diabet Med* 2014;31:647–56.
- [17] Tao L, Wilson EC, Wareham NJ, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabet Med* 2015;32:907–19.
- [18] Laxy M, Wilson E, Boothby C, Griffin S. How good are GPs at adhering to a pragmatic trial protocol in primary care? Results from the ADDITION-Cambridge cluster-randomized pragmatic trial. *BMJ Open* 2017 [In Press].
- [19] Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. *J Health Serv Res Policy* 1997;2:26–30.
- [20] Banta HD, Thacker SB. The case for reassessment of health care technology: once is not enough. *JAMA* 1990;264:235–40.
- [21] Wilson E, Abrams K. From evidence-based economics to economics-based evidence: using systematic review to inform the design of future research. In: Shemilt I, Mugford M, Vale L, et al., eds. *Evidence-Based Decisions and Economics* (2nd ed.). London: Blackwell Publishing, 2010.
- [22] McIntosh AHA, Home PD, Brown F, et al. *Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose*. Sheffield, UK: University of Sheffield, 2001.
- [23] McIntosh AHA, Home PD, Brown F, et al. *Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Pressure*. Sheffield, UK: University of Sheffield, 2002.
- [24] McIntosh AHA, Home PD, Brown F, et al. *Clinical Guidelines and Evidence Review for Type 2 Diabetes: Lipids Management*. Sheffield, UK: University of Sheffield, 2002.
- [25] Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ* 2008;336:491–5.
- [26] Personal Social Services Research Unit. Unit costs of health and social care. Available from: <http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf> [Accessed February 5, 2015].
- [27] gov.uk. National schedule of reference costs 2009–10 for NHS trusts. Available from: <https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010>. [Accessed February 5, 2015].
- [28] data.gov.uk. Prescription cost analysis, England. Available from: <http://data.gov.uk/dataset/prescription-cost-analysis-england>. [Accessed February 15, 2015].
- [29] Jones AM, Lomas J, Moore PT, Rice N, et al. A quasi-Monte-Carlo comparison of parametric and semiparametric regression methods for heavy-tailed and non-normal data: an application to healthcare costs. *J R Stat Soc Ser A Stat Soc* 2016;179:951–74.
- [30] Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. *Health Econ* 2011;20:897–916.
- [31] Mansournia MA, Altman DG. Inverse probability weighting. *BMJ* 2016;352:i189.
- [32] Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). *Diabetologia* 2004;47:1747–59.
- [33] Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. *Med Decis Making* 2012;32:690–700.
- [34] Tao L, Wilson EC, Griffin SJ, Simmons RK, ADDITION-Europe Study Team. Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort. *Value Health* 2013;16:1074–80.
- [35] Sandbaek A, Griffin SJ, Sharp SJ, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study. *Diabetes Care* 2014;37:2015–23.
- [36] Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). *Med Decis Making* 2002;22:340–9.
- [37] Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive 06: cost-effectiveness of pioglitazone in type 2 diabetes in the UK. *Diabet Med* 2007;24:982–1002.
- [38] Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. *Diabetes Obes Metab* 2008;1:43–55.
- [39] Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). *Diabet Med* 2003;20:442–50.
- [40] National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: <https://www.nice.org.uk/article/pmg9/chapter/the-reference-case>. [Accessed November 2, 2015].
- [41] Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ* 2013;346:f1049.
- [42] National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: <https://www.nice.org.uk/process/pmg9/chapter/the-reference-case#discounting>. [Accessed April 25, 2017].
- [43] Curtis L. *Unit Costs of Health and Social Care 2010*. Canterbury, Kent: Personal Social Services Research Unit, University of Kent, 2010.
- [44] Curtis L, Burns A. *Unit Costs of Health and Social Care 2015*. Canterbury, Kent: Personal Social Services Research Unit, University of Kent, 2015.
- [45] MedicinesComplete. British National Formulary. Available from: <https://www.bnf.org/>. [Accessed April 25, 2017].
- [46] Department of Health. NHS reference costs 2009–2010. Available from: <https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010>. [Accessed April 25, 2017].
- [47] Department of Health. NHS reference costs 2015 to 2016. Available from: <https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016>. [Accessed April 25, 2017].
- [48] Briggs A, Claxton K, Sculpher M. *Decision Modelling for Health Economic Evaluation*. New York, NY: Oxford University Press, 2006.